Cody is the parent of a pediatric liver recipient. His daughter received a liver transplant in 2021 at Texas Children's Hospital after she was diagnosed with Biliary Atresia shortly after she was born in 2019 at Oklahoma Children's Hospital. He credits the transplant team and surgeons for allowing his daughter to thrive after her transplant. Cody serves as member on the OPTN board of directors, and a member of the Biliary Atresia Research and Education (BARE) Taskforce.
Pediatric Gastroenterologist and Transplant Hepatologist
Transplant Hepatologist, Nazih Zhudi Transplant Institute.
Dr. Kono is a transplant hepatologist at UC San Diego, with expertise in liver imaging and hepatocellular carcinoma (HCC) diagnosis. She graduated from Kyoto University School of Medicine and trained in hepatology and radiology. Dr. Kono is a recognized leader in contrast-enhanced ultrasound (CEUS), particularly for liver imaging. She has published 107 peer-reviewed articles and chaired the CEUS LI-RADS working group from 2014 to 2020, during which she established the CEUS LI-RADS algorithm.
Hi! My name is Varun, and I'm an MS-4 at Weill Cornell Medicine interested in applying into Diagnostic Radiology
I'm on a mission against liver disease and perhaps metabolic syndromes too. My secret weapon? Applying modern rigor to traditional herbal medicine. Yes, my lab coat often smells like a fancy apothecary—it's a great combo.
Postdoctoral Research Fellow at UT Southwestern Medical Center. Passionate about advancing liver disease research and improving patient outcomes, with a strong interest in public health and health equity.
Associate Professor Medicine, Universty of Toronto<br>Staff Hepatologist, Toronto General Hospital<br>Education Committee, Canadian Association for the Study of the LIver<br>Education Lead, AASLD HBV SIG<br>
Dr. Tai-Chung Tseng is an Associate Professor and an attending physician at National Taiwan University Hospital in Taipei, Taiwan. He completed his doctoral research under the mentorship of Prof. Jia-Horng Kao and received his Ph.D. degree in 2013. Dr. Tseng's research primarily focuses on the long-term prognosis of chronic hepatitis B (CHB) carriers, particularly investigating how viral and host factors influence disease outcomes.<br>One of Dr.
Dr. Gongxin He is a distinguished pharmaceutical scientist and entrepreneur with a career spanning over three decades in innovative drug research and development. He earned his PhD in Synthetic Chemistry from Kyushu University (Japan) in 1988 and conducted his postdoctoral research at the University of California, Santa Barbara.<br>Dr. He's most notable contribution came during his career at Gilead Sciences (1992-2018), where he was the principal inventor and project leader for tenofovir alafenamide (TAF).